Proteon Therapeutics (NASDAQ:PRTO) & BioCardia (NASDAQ:BCDA) Head to Head Review

Proteon Therapeutics (NASDAQ:PRTO) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Earnings & Valuation

This table compares Proteon Therapeutics and BioCardia’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics N/A N/A -$20.73 million ($1.15) -0.26
BioCardia $630,000.00 49.83 -$13.99 million N/A N/A

BioCardia has higher revenue and earnings than Proteon Therapeutics.

Profitability

This table compares Proteon Therapeutics and BioCardia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A N/A -118.68%
BioCardia -2,191.28% -423.10% -227.05%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Proteon Therapeutics and BioCardia, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 4 1 0 2.20
BioCardia 0 0 3 0 3.00

Proteon Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 1,010.37%. BioCardia has a consensus price target of $18.33, suggesting a potential upside of 298.55%. Given Proteon Therapeutics’ higher probable upside, equities analysts clearly believe Proteon Therapeutics is more favorable than BioCardia.

Insider & Institutional Ownership

25.6% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 1.0% of BioCardia shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 26.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Proteon Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

Summary

Proteon Therapeutics beats BioCardia on 6 of the 11 factors compared between the two stocks.

About Proteon Therapeutics

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.